On June 15th, Shenzhen Zhenwei Biotechnology Co., Ltd. (referred to as "Zhenwei Biotech") was granted the first tobacco monopoly production enterprise license (aerosolized substance) in the electronic cigarette industry. This signifies that Zhenwei Biotech, as a leading company in the aerosolized substance subsector, has officially passed the strict review of the State Tobacco Monopoly Administration, becoming one of the few enterprises granted a tobacco monopoly production enterprise license.
The issuance of the tobacco monopoly production license signifies an important and solid step for China in promoting the legalization and standardization of the electronic cigarette industry. In this new landscape, Zhenwei Biotechnology will continue to uphold its mission to "lead industry development and promote healthy vaping," with a focus on prioritizing national and consumer interests. The company is committed to becoming a trusted global electronic vaping liquid solution service platform, delivering happiness to its employees and remaining a leader in the industry.
Since the implementation of the "Electronic Cigarette Management Regulations" on May 1, 2022, the State Tobacco Monopoly Administration has rapidly promoted the regulation of new tobacco products such as electronic cigarettes, demonstrating the government's determination to promote the standardized development of the electronic cigarette industry and effectively improve market access barriers. True Taste Biotech actively embraces regulation, operates in compliance with the law, and with its long-term accumulation of good reputation in the industry, is expected to further increase market share in the future's competition for the industry's benign development.
The Chinese e-cigarette industry, which currently has over 90% of global production capacity, will further solidify its advantages as an industry cluster and gain international recognition under more standardized regulations, ultimately contributing to the country's economy. With the entire production chain, including raw materials, production, wholesaling, sales, and exports, regulated similarly to traditional cigarettes, product quality will be effectively monitored, and consumer rights will be better protected. True Taste Biotech will actively adhere to the principle of "prioritizing both benefits," embrace new regulations, and contribute to the sustainable development of the e-cigarette industry.
For more information on regulatory policy updates, please visit: https://cn.2firsts.com/#/?page_id=16.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
